Ovarian suppression with a gonadotropin-releasing hormone agonist does not alter insulin-stimulated glucose disposal

被引:10
作者
Cooper, Brian C.
Sites, Cynthia K.
Casson, Peter R.
Toth, Michael J.
机构
[1] Univ Vermont, Dept Obstet & Gynecol, Burlington, VT 05405 USA
[2] Univ Vermont, Dept Med, Burlington, VT 05405 USA
关键词
ovarian hormones; estrogen; insulin sensitivity; GnRH agonist;
D O I
10.1016/j.fertnstert.2006.11.045
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Aging is associated with reduced tissue sensitivity to insulin. In women, these age-related changes may be accelerated by menopause. The effect of ovarian hormone deficiency on tissue insulin sensitivity in humans, however, has not been defined clearly. Thus, the goal of this study was to evaluate the effect of suppression of endogenous ovarian hormone production on insulin-stimulated glucose disposal. Design: Randomized, single-blind, placebo-controlled trial. Setting: General clinical research center. Patients: Thirteen healthy, nonobese premenopausal women. Intervention(s): Insulin-stimulated glucose disposal was determined by hyperinsulinemic (40 mU/m(2)/min) clamp during the early to midfollicular and midluteal phase of the menstrual cycle. Volunteers then received 2 months of treatment with the GnRH agonist (GnRHa) leuprolide acetate (n = 6) or placebo (n = 7) and were retested. Main Outcome Measure(s): Total, oxidative, and nonoxidative insulin-stimulated glucose disposal. Result(s): Because no effect of cycle phase was found on total, oxidative, or nonoxidative glucose disposal, pretreatment follicular and luteal phase values were averaged. Treatment with GnRHa had no effect on total glucose disposal (GnRHa: 1.0.6 +/- 0.9 to 10.8 +/- 0.9 vs. placebo: 10.2 +/- 0.7 to 10.4 +/- 1.0 mg/kg fat-free mass/min, P = .99). Similarly, there was no effect of GnRHa administration on oxidative (GnRHa: 2.77 +/- 0.58 to 3.89 +/- 0.58 vs. placebo: 2.74 +/- 0.42 to 3.33 +/- 0.62 mg/kg fat-free mass/min, P = .52; n = 6 and 6, respectively) or nonoxidative (GnRHa: 7.82 +/- 0.68 to 6.91 +/- 0.66 vs. placebo: 7.94 +/- 0.72 to 7.79 +/- 0.99 mg/kg fat-free mass/min, P = .59; n = 6 and 6, respectively) components of glucose disposal. Conclusion(s): Our results suggest that endogenous ovarian hormones do not regulate tissue responsiveness to insulin or intracellular pathways of glucose disposal.
引用
收藏
页码:1131 / 1138
页数:8
相关论文
共 50 条
[41]   TRIGGERING OF OVULATION USING A GONADOTROPIN-RELEASING-HORMONE AGONIST DOES NOT PREVENT OVARIAN HYPERSTIMULATION SYNDROME [J].
VANDERMEER, S ;
GERRIS, J ;
JOOSTENS, M ;
TAS, B .
HUMAN REPRODUCTION, 1993, 8 (10) :1628-1631
[42]   Does gonadotropin-releasing hormone agonist cause luteolysis by inducing apoptosis of the human granulosa-luteal cells? [J].
Gonen, Noa ;
Casper, Robert F. ;
Jurisicova, Andrea ;
Yung, Yuval ;
Friedman-Gohas, Moran ;
Orvieto, Raoul ;
Haas, Jigal .
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2021, 38 (09) :2301-2305
[43]   Dual Trigger with Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin Improves Live Birth Rate for Women with Expected Normal Ovarian Response in Gonadotropin Releasing Hormone Antagonist Cycles: Retrospective Study [J].
Tulek, Firat ;
Kahraman, Alper .
JOURNAL OF CLINICAL OBSTETRICS AND GYNECOLOGY, 2021, 31 (03) :89-96
[44]   Functional Ovarian Cysts in Artificial Frozen-Thawed Embryo Transfer Cycles With Depot Gonadotropin-Releasing Hormone Agonist [J].
Ji, Hui ;
Su, Yan ;
Zhang, Mianqiu ;
Li, Xin ;
Li, Xiuling ;
Ding, Hui ;
Dong, Li ;
Cao, Shanren ;
Zhao, Chun ;
Zhang, Junqiang ;
Shen, Rong ;
Ling, Xiufeng .
FRONTIERS IN ENDOCRINOLOGY, 2022, 13
[45]   No association between LH levels and ovarian response in oocyte donors triggered with gonadotropin-releasing hormone agonist: A prospective study [J].
Blazquez, Anna ;
Falco, Noelia ;
Cano, Elena ;
Rodriguez, Flavia ;
Vassena, Rita ;
Miguel-Escalada, Irene ;
Popovic, Mina ;
Rodriguez, Amelia .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2024, 294 :163-169
[46]   Does the repeat dose of gonadotropin-releasing hormone agonist trigger in polycystic ovarian syndrome improve in vitro fertilization cycles outcome? A clinical trial study [J].
Aflatoonian, Abbas ;
Haghighi, Fatemeh ;
Hoseini, Masrooreh ;
Haghdani, Saeid .
INTERNATIONAL JOURNAL OF REPRODUCTIVE BIOMEDICINE, 2020, 18 (07) :485-490
[47]   Ovarian stimulation in in vitro fertilization with or without the "long" gonadotropin-releasing hormone agonist protocol: effect on cycle duration and outcome [J].
Beloosesky, R ;
Kol, S ;
Lightman, A ;
Itskovitz-Eldor, J .
FERTILITY AND STERILITY, 2000, 74 (01) :166-168
[48]   Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF [J].
Fasouliotis, SJ ;
Laufer, N ;
Sabbagh-Ehrlich, S ;
Lewin, A ;
Hurwitz, A ;
Simon, A .
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2003, 20 (11) :455-460
[49]   Protective effect of gonadotropin-releasing hormone agonist against chemotherapy-induced ovarian dysfunction: A meta-analysis [J].
Zheng, Fei ;
Zhu, Bin ;
Feng, Qingjing ;
Wu, Lili ;
Cui, Yuechong ;
Liu, Yumo ;
Wang, Yingqian .
ONCOLOGY LETTERS, 2019, 17 (06) :5319-5326
[50]   Gonadotropin-Releasing Hormone Agonist Versus Recombinant Human Chorionic Gonadotropin Triggering in Fertility Preservation Cycles [J].
Herzberger, Einat Haikin ;
Knaneh, Sabaa ;
Amir, Hadar ;
Reches, Adi ;
Ben-Yosef, Dalit ;
Kalma, Yael ;
Azem, Foad ;
Samara, Nivin .
REPRODUCTIVE SCIENCES, 2021, 28 (12) :3390-3396